Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

鲁索利替尼 药代动力学 医学 内科学 毒性 观察研究 人口 临床试验 肿瘤科 药理学 曲线下面积 队列 药品 探索性分析 人口研究 队列研究 分配量 槽浓度 加药 基于生理学的药代动力学模型 体表面积
作者
Jérémie Tachet,Sara C. Meyer,Francesco Grandoni,Emmanuel Haefliger,Monika Nagy-Hulliger,Jörg P. Halter,Jakob Robert Passweg,David Haefliger,Carine Bardinet,Laurent Arthur Decosterd,Monia Guidi,François Girardin
出处
期刊:Clinical Pharmacology & Therapeutics [Wiley]
卷期号:120 (3): 753-761 被引量:2
标识
DOI:10.1002/cpt.70367
摘要

Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring. In total, 221 steady‐state ruxolitinib concentrations from 77 adult patients enrolled across several centers in Switzerland were analyzed. Demographic and clinical data were recorded at each visit. Population pharmacokinetic (popPK) analysis was performed with MonolixSuite® 2024R1 (Lixoft, France). Model‐based simulations were used to predict trough concentration ( C min ) and the area under the concentration–time curve over 24 h (AUC 24 ) for the recommended dosage regimens, as a function of covariates. An exploratory pharmacokinetic/pharmacodynamic analysis was conducted in the overall cohort. Ruxolitinib PK was characterized by a marked between‐subject variability in clearance (45%). Strong cytochrome (CYP) 3A4 or dual CYP2C9/CYP3A4 inhibitors reduced clearance by 39%. At 10 mg twice daily, model‐based simulations showed CYP inhibitors increased median C min and AUC 24 by 2.9‐ and 1.7‐fold, respectively. Still, no significant exposure–efficacy relationship was identified. However, higher ruxolitinib exposure tended to be associated with increased toxicity in the overall population ( C min and AUC 24 , P ≈0.02–0.03). In clinical practice, ruxolitinib exposure shows substantial variability and is strongly affected by strong CYP inhibitors that are frequently co‐administered. Whilst no clear exposure–efficacy relationship was observed, higher exposure was linked to increased toxicity risk, arguing for careful dose adjustment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LL发布了新的文献求助10
1秒前
Charming发布了新的文献求助10
1秒前
会撒娇的面包完成签到,获得积分10
2秒前
Makoto1377发布了新的文献求助10
3秒前
从此发布了新的文献求助10
3秒前
3秒前
4秒前
赘婿的应助被ki采纳,获得10
4秒前
同心源完成签到 ,获得积分20
5秒前
盗梦师完成签到 ,获得积分10
5秒前
9秒前
故渊丶发布了新的文献求助10
9秒前
li完成签到 ,获得积分10
9秒前
O耶完成签到,获得积分10
9秒前
香蕉觅云的应助被周周采纳,获得30
9秒前
9秒前
英俊的铭的应助被kjh采纳,获得10
10秒前
11秒前
秋风的应助被科研辣鸡采纳,获得10
11秒前
16秒前
12345发布了新的文献求助10
16秒前
共享精神的应助被搞怪的乐荷采纳,获得10
16秒前
17秒前
17秒前
17秒前
kk子的应助被Glllll采纳,获得20
17秒前
浮云客发布了新的文献求助10
17秒前
赤道永恒完成签到,获得积分10
19秒前
19秒前
20秒前
20秒前
霍霍发顶刊完成签到 ,获得积分10
20秒前
大个的应助被科研通管家采纳,获得10
20秒前
20秒前
20秒前
Jasper的应助被葡萄小伊ovo采纳,获得10
20秒前
20秒前
852的应助被葡萄小伊ovo采纳,获得10
20秒前
茉莉雨的应助被科研通管家采纳,获得10
21秒前
天天快乐的应助被葡萄小伊ovo采纳,获得10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183601
求助须知:如何正确求助?哪些是违规求助? 9572875
关于积分的说明 21827816
捐赠科研通 7780716
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558197
邀请新用户注册赠送积分活动 2480485